Angiogenesis, a target for tumor therapy

Journal of Laboratory and Clinical Medicine

Volumn 132, Issue 5, 1998, Pages 363-368

  Griffioen, Arjan W ^a   Barendsz Janson, Annemarie F ^b   Mayo, Kevin H ^b   Hillen, Harry F P ^b  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0032212115     PISSN: 00222143     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-2143(98)90106-8     Document Type: Review

References (46)

1. Folkman J. Tumor angiogenesis: therapeutic implications, N Engl J Med 1971;285:1182-6.
2. Folkman J. Tumor angiogenesis. In: Mendelsohn J, Howley P, Liotta L, Israel M, editors. The molecular basis of cancer. Philadelphia: WB Saunders; 1995.
3. Rastinejad F, Polverini PJ, Bouck N. Regulation of the activity of a new inhibitor of angiogenesis by a cancer suppressor gene. Cell 1989;56:345-55.
4. Dameron KM, Volpert OV, Tainsky MA, Bouck N. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 1994;265:1582-4.
5. Kusaka M, Sudo K, Fujita T, et al. Potent anti-angiogenic action of AGM-1470: comparison to the fumagillin parent. Biochem Biophys Res Commun 1991;174:1070-6.
6. Castronovo V, Belotti D. TNP-470 (AGM-1470): mechanisms of action and early clinical development. Eur J Cancer 1996;32A:2520-7.
7. O'Reilly MS, Holmgren L, Shing Y, et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994;79:315-28.
8. O'Reilly MS, Boehm T, Shing Y, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997;88:277-85.
9. Boehm T, Folkman J, Browder T, O'Reilly MS. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 1997;390:404-7.
10. Black WR, Agner RC. Tumour regression after endostatin therapy. Nature 1998;391:450.
11. Rasmussen HS, McCann PP. Matrix metalloproteinase inhibition as a novel anticancer strategy: a review with special focus on batimastat and marimastat. Pharmacol Ther 1997;75:69-75.
12. Brooks PC, Silletti S, vonSchalscha TL, Friedlander M, Cheresh DA. Disruption of angiogenesis by PEX, a noncatalytic metalloproteinase fragment with integrin binding activity. Cell 1998;92:391-400.
13. Burrows FJ, Thorpe PE. Eradication of large solid tumors in mice with an immunotoxin directed against tumor vasculature. Proc Natl Acad Sci USA 1993;90:8996-9000.
14. Huang X, Molema G, King S, Watkins L, Edgington TS, Thorpe PE. Tumor infarction in mice by antibody-directed targeting of tissue factor to tumor vasculature. Science 1997;275:547-50.
15. Arap W, Pasqualini R, Ruoslahti E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 1998;279:377-80.
16. Sidky YA, Auerbach R. Lymphocyte-induced angiogenesis: a quantitative and sensitive assay of the graft-vs-host reaction. J Exp Med 1975;141:1084-100.
17. Polverini PJ, Cotran PS, Gimbrone MA Jr, Unanue ER. Activated macrophages induce vascular proliferation. Nature 1977;269:804-6.
18. Camussi G, Montrucchio G, Lupia E, Soldi R, Comoglio PM, Bussolino F. Angiogenesis induced in vivo by hepatocyte growth factor is mediated by platelet-activating factor synthesis from macrophages. J Immunol 1997;158:1302-9.
19. Koch AE, Polverini PJ, Kunkel SL, et al. Interleukin-8 as a macrophage-derived mediator of angiogenesis. Science 1992;258:1798-801.
20. Hashimoto M, Shingu M, Ezaki I, et al. Production of soluble ICAM-1 from human endothelial cells induced by IL-1 beta and TNF-alpha. Inflammation 1994;18:163-73.
21. Richardson M, Hadcock SJ, Dereske M, Cybulsky MI. Increased expression in vivo of VCAM-1 and E-selectin by the aortic endothelium of normolipemic and hyperlipemic diabetic rabbits. Arterioscler Thromb 1994;14:760-9.
22. Vanhee D, Delneste Y, Lassalle P, Gosset P, Joseph M, Tonnel AB. Modulation of endothelial cell adhesion molecule expression in a situation of chronic inflammatory stimulation. Cell Immunol 1994;155:446-56.
23. Shimizu Y, Newman W, Tanaka Y, Shaw S. Lymphocyte interactions with endothelial cells. Immunol Today 1992;13:106-12.
24. Swerlick RA, Lee KH, Li LJ, Sepp NT, Caughman SW, Lawley TJ. Regulation of vascular cell adhesion molecule 1 on human dermal microvascular endothelial cells. J Immunol 1992;149:698-705.
25. Ruco LP, Pomponi D, Pigott R, et al. Cytokine production (IL-1 alpha, IL-1 beta, and TNF alpha) and endothelial cell activation (ELAM-1 and HLA-DR) in reactive lymphadenitis, Hodgkin's disease, and in non-Hodgkin's lymphomas. An immunocytochemical study. Am J Pathol 1990;137:1163-71.
26. Pober JS, Gimbrone MAJ, Lapierre LA, et al. Overlapping patterns of activation of human endothelial cells by interleukin 1, tumor necrosis factor, and immune Interferon. J Immunol 1986;137:1893-6.
27. Gamble JR, Vadas MA. Endothelial cell adhesiveness for human T lymphocytes is inhibited by transforming growth factor-beta 1. J Immunol 1991;146:1149-54.
28. Gamble JR, Vadas MA. Endothelial adhesiveness for blood neutrophils is inhibited by transforming growth factor-beta. Science 1988;242:97-9.
29. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996;86:353-64.
30. Griffioen AW, Damen CA, Martinotti S, Blijham GH, Groenewegen G. Endothelial ICAM-1 expression is suppressed in human malignancies: role of angiogenic factors. Cancer Res 1996;56:1111-7.
31. Wu NZ, Klitzman B, Dodge R, Dewhirst MW. Diminished leukocyte-endothelium interaction in tumor microvessels. Cancer Res 1992;52:4265-8.
32. Piali L, Fichtel A, Terpe HJ, Imhof BA, Gisler RH. Endothelial vascular cell adhesion molecule 1 expression is suppressed by melanoma and carcinoma. J Exp Med 1995;181:811-6.
33. Kitayama J, Nagawa H, Yasuhara H, et al. Suppressive effect of basic fibroblast growth factor on transendothelial emigration of CD4(+) T-lymphocyte. Cancer Res 1994;54:4729-33.
34. Melder RJ, Koenig GC, Witwer BP, Safabakhsh N, Munn LL, Jain RK. During angiogenesis, vascular endothelial growth factor and basic fibroblast growth factor regulate natural killer cell adhesion to tumor endothelium. Nature Med 1996;2:992-7.
35. Jain RK, Koenig GC, Dellian M, Fukumura D, Munn LL, Melder RJ. Leukocyte-endothelial adhesion and angiogenesis in tumors. Cancer Metastasis Rev 1996;15:195-204.
36. Schlingemann RO, Rietveld FJ, Kwaspen F, van de Kerkhof PC, de Waal RM, Ruiter DJ. Differential expression of markers for endothelial cells, pericytes, and basal lamina in the microvasculature of tumors and granulation tissue. Am J Pathol 1991;138:1335-47.
37. Renkonen R, Paavonen T, Nortamo P, Gahmberg CG. Expression of endothelial adhesion molecules in vivo. Increased endothelial ICAM-2 expression in lymphoid malignancies. Am J Pathol 1992;140:763-7.
38. Kuzu I, Bicknell R, Fletcher CD, Gatter KC. Expression of adhesion molecules on the endothelium of normal tissue vessels and vascular tumors. Lab Invest 1993;69:322-8.
39. Doussis Anagnostopoulou I, Kaklamanis L, Cordell J, et al. ICAM-3 expression on endothelium in lymphoid malignancy. Am J Pathol 1993;143:1040-3.
40. Griffioen AW, Damen CA, Blijham GH, Groenewegen G. Tumor angiogenesis is accompanied by a decreased inflammatory response of tumor associated endothelium. Blood 1996;88:667-73.
41. Griffioen AW. Phenotype of the tumor vasculature: cell adhesion as a target for tumor therapy. Cancer J 1997;10:249-55.
42. Relou IAM, Damen CA, Van der Schaft DWJ, Groenewegen G, Griffioen AW. The effect of culture conditions on endothelial cell phenotype and responsiveness. Tissue Cell. In press.
43. Taylor S, Folkman J. Protamine is an inhibitor of angiogenesis. Nature 1982;297:307-12.
44. Gupta SK, Singh JP. Inhibition of endothelial cell proliferation by platelet factor-4 involves a unique action on S phase progression. J Cell Biol 1994;127:1121-7.
45. Gupta SK, Hassel T, Singh JP. A potent inhibitor of endothelial cell proliferation is generated by proteolytic cleavage of the chemokine platelet factor 4. Proc Natl Acad Sci USA 1995;92:7799-803.
46. Barendsz-Janson AF, Griffioen AW, Muller AD, Van DamMieras MCE, Hillen HFP. In vitro tumor angiogenesis assays: plasminogen lysine binding site 1 (LBS-1) inhibits in vitro tumor induced angiogenesis. J Vasc Res 1998;35:109-14.